Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Completed 3Recruiting 2

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 37Breast 33Gynecologic 19Thoracic 13Head & Neck 12Sarcoma 7Dermatologic 7CNS 6Tumor-Agnostic 5Genitourinary 5Other solid neoplasm 3Lymphoid 1

Conditions

Neoplasms 5

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Indocyanine Green × Tumor-Agnostic × Clear all
NCT04752137 2026-04-24

Intraoperative Tumor Margin Identification With ICG Dye Imaging

Massachusetts General Hospital

Phase 2 Recruiting
100 enrolled
Tumor-Agnostic

Neoplasms

NCT04723810 2026-03-09

TumorGlow Intraoperative Molecular Imaging (IMI)

University of Pennsylvania

Phase 1/2 Recruiting
500 enrolled
Tumor-Agnostic

Neoplasms

NCT02280954 2018-03-20

818012

University of Pennsylvania

Phase 1 Completed
48 enrolled
Tumor-Agnostic

Neoplasms

NCT02621268 2018-03-20

ICG

University of Pennsylvania

Phase 1 Completed
48 enrolled
Tumor-Agnostic

Neoplasms

NCT01884584 2017-03-09

Potential Use of Indocyanine Green as a Fluorescent Agent for Definition of Surgical Margins in Cancer

Emory University

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡